Consensus Erasca, Inc.

Stocks

ERAS

US29479A1088

Biotechnology & Medical Research

Market Closed - Nasdaq 20:00:00 30/10/2026 GMT			5-day change	1st Jan Change
14.35 ^USD	-4.21%		-0.28%	+285.75%

10-16	Erasca Chief Operating Officer to Depart; Shares Fall	MT
10-16	Erasca, Inc. Announces Termination of Nicholas Chetwyn as Chief Operating Officer, Effective November 2, 2026	CI

Evolution of the Average Target: Erasca, Inc.

Evolution of the Target Price: Erasca, Inc.

Changes in Analyst Recommendations: Erasca, Inc.

fd644882afe5f082.b3jYmRBgjxkzaWQd0g_slyaS6CucTdx93O3vdoLuG8o.GgiVtF4L3n5LIlRXukO4z2PVi1LXA7EWsKCYFdfYeqE_S-mpSTHtbQERXA~4e3baccbfad6eba200db120949f7601a

Analysts' recommendations: Erasca, Inc.

08-14	BofA Adjusts Price Target on Erasca to $20 From $18	MT
06-04	Erasca Shares Rise After BofA Upgrade	MT
06-04	Erasca Sees More Balanced Outlook as Early RAS Data Support Clinical Activity, BofA Says	MT
06-04	BofA Securities Upgrades Erasca to Neutral From Underperform, Adjusts Price Target to $16 From $9	MT
04-27	Mizuho Raises Price Target on Erasca to $28 From $19, Keeps Outperform Rating	MT
03-13	Mizuho Raises Price Target on Erasca to $19 From $16, Keeps Outperform Rating	MT
01-27	Mizuho Raises Price Target on Erasca to $16 From $5, Keeps Outperform Rating	MT
01-26	Morgan Stanley Raises Price Target on Erasca to $10 From $4, Keeps Equalweight Rating	MT
01-07	Piper Sandler Initiates Erasca at Overweight With $5 Price Target	MT
01-06	BofA Adjusts Price Target on Erasca to $2 From $1, Maintains Underperform Rating	MT
12-09	Mizuho Raises Price Target on Erasca to $5 From $4, Keeps Outperform Rating	MT
16/10/25	Stifel Nicolaus Initiates Coverage on Erasca With Buy Rating, $4 Price Target	MT
03/09/25	BofA Securities Downgrades Erasca to Underperform	MT
18/08/25	Erasca Shares Fall After Downgrade From Morgan Stanley	MT
18/08/25	Morgan Stanley Downgrades Erasca to Equalweight From Overweight, Cuts Price Target to $2 From $4	MT
28/07/25	Mizuho Cuts Price Target on Erasca to $4 From $7, Keeps Outperform Rating	MT
26/03/25	Raymond James Initiates Erasca at Outperform With $5 Price Target	MT
07/01/25	BofA Securities Upgrades Erasca to Buy From Neutral, Maintains $5 Price Target	MT
18/11/24	Jefferies Initiates Erasca at Buy With $6 Price Target	MT
02/04/24	Goldman Sachs Adjusts Erasca's Price Target to $7 From $6, Maintains Buy Rating	MT
11/03/24	Capital One Initiates Erasca at Overweight Rating With $8 Price Target	MT
28/11/23	HC Wainwright Cuts Erasca Price Target to $8 From $10, Maintains Buy Rating	MT
11/10/23	HC Wainwright Initiates Erasca at Buy Rating With $10 Price Target	MT
06/06/23	Evercore ISI Adjusts Erasca's Price Target to $11 From $20, Keeps Outperform Rating	MT
06/06/23	Mizuho Securities Adjusts Erasca Price Target to $8 From $9, Maintains Buy Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ERASCA, INC.					+68.02%
	WUXI APPTEC CO., LTD.					+42.48%
	ARGENX SE					+24.46%
	LONZA GROUP AG					+8.88%
	IQVIA HOLDINGS INC.					+15.87%
	BEONE MEDICINES AG					+17.86%
	REVOLUTION MEDICINES, INC.					+35.3%
	GENMAB A/S					+1.94%
	CELLTRION, INC.					+41.27%
	INSMED INCORPORATED					+72.28%
	Average					+32.84%
	Weighted average by Cap.					+27.59%